SGHT: Record growth and lower cash burn underpin a higher FY26 revenue outlook

What happened

Sight Sciences reported record third-quarter revenue of $24.9 million, up 25% from a year earlier, and said cash use improved sharply. It raised its fiscal-year revenue outlook to $92 million–$93 million while keeping adjusted operating expense guidance unchanged, citing TearCare and OMNI as growth drivers.

Confirmed

Global impact / market context

Higher revenue guidance suggests the company expects its sales momentum to continue, while unchanged adjusted operating expense guidance limits the stated increase in planned costs. If sales grow without a comparable rise in spending, more cash could remain available, but the article gives no detailed cash figures.

Analyst inference

The update combines faster reported sales with lower cash use, potentially easing concern about the resources needed to support growth. For investors, the key question is whether TearCare and OMNI can sustain revenue gains without pushing operating costs or cash consumption higher.

Analyst inference

What to watch

1. Compare future quarterly revenue with the $92 million–$93 million fiscal-year outlook to assess whether sales growth continues at the pace implied by the raised guidance. Analyst inference
2. Check later reports for cash use and adjusted operating expenses; sustained improvement would suggest growth is not requiring a comparable increase in spending. Analyst inference
3. Look for updates on TearCare and OMNI sales contributions, since the article names these products as growth drivers but provides no product-level revenue figures. Confirmed

Evidence

• Original source link unavailable